ATE243691T1 - Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel - Google Patents

Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel

Info

Publication number
ATE243691T1
ATE243691T1 AT97947107T AT97947107T ATE243691T1 AT E243691 T1 ATE243691 T1 AT E243691T1 AT 97947107 T AT97947107 T AT 97947107T AT 97947107 T AT97947107 T AT 97947107T AT E243691 T1 ATE243691 T1 AT E243691T1
Authority
AT
Austria
Prior art keywords
represents hydrogen
methyl
fluorine
pct
chlorine
Prior art date
Application number
AT97947107T
Other languages
English (en)
Inventor
Bernard Vacher
Bernard Bonnaud
Wouter Koek
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE243691T1 publication Critical patent/ATE243691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97947107T 1996-11-21 1997-11-20 Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel ATE243691T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614217A FR2755967B1 (fr) 1996-11-21 1996-11-21 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
PCT/FR1997/002097 WO1998022459A1 (fr) 1996-11-21 1997-11-20 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number Publication Date
ATE243691T1 true ATE243691T1 (de) 2003-07-15

Family

ID=9497861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947107T ATE243691T1 (de) 1996-11-21 1997-11-20 Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel

Country Status (14)

Country Link
US (1) US6020345A (de)
EP (1) EP0946546B1 (de)
JP (1) JP4248605B2 (de)
CN (1) CN1098263C (de)
AT (1) ATE243691T1 (de)
AU (1) AU732470B2 (de)
BR (1) BR9713126B1 (de)
CA (1) CA2272460C (de)
DE (1) DE69723104T2 (de)
DK (1) DK0946546T3 (de)
ES (1) ES2202647T3 (de)
FR (1) FR2755967B1 (de)
PT (1) PT946546E (de)
WO (1) WO1998022459A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2359244C (en) * 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US8106074B2 (en) * 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
AU2002351196A1 (en) * 2001-12-03 2003-06-17 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP2324825A1 (de) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
SI1580188T1 (sl) * 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
KR100435105B1 (ko) * 2002-04-17 2004-06-09 금호석유화학 주식회사 카르복시이미데이트 리간드에 기초한 원자이동 라디칼중합을 이용한 새로운 메틸메타아크릴레이트의 중합방법
FR2840900B1 (fr) * 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
FR2852244B1 (fr) 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) * 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
EP2058306A1 (de) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituierte 2-Pyridinylmethylaminderivate
WO2012145617A2 (en) * 2011-04-22 2012-10-26 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
MX374938B (es) 2014-07-09 2025-03-06 Pf Medicament Un método para el tratamiento de trastornos del movimiento con befiradol.
EP3260452A1 (de) * 2016-06-24 2017-12-27 Neurolixis Verbindungen zur behandlung von serotoninsensitiven erkrankungen gesteuert durch 5-ht1a rezeptoren
WO2018057576A1 (en) 2016-09-22 2018-03-29 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
EP3664787B1 (de) 2017-07-20 2022-07-20 Neurolixis Verwendung von selektiven serotin-5-ht1a-rezeptor-agonisten zur behandlung von nebenwirkungen von vmat-inhibitoren
AU2024238367A1 (en) 2023-03-19 2025-10-09 Neurolixis, Inc. Method for treating l-dopa-induced dyskinesia using befiradol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
EP0661266A1 (de) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituierte cyclische Aminverbindungen als 5HT2 Antagonisten

Also Published As

Publication number Publication date
DE69723104T2 (de) 2004-04-29
FR2755967A1 (fr) 1998-05-22
US6020345A (en) 2000-02-01
WO1998022459A1 (fr) 1998-05-28
AU732470B2 (en) 2001-04-26
CN1098263C (zh) 2003-01-08
EP0946546A1 (de) 1999-10-06
DK0946546T3 (da) 2003-10-20
BR9713126B1 (pt) 2009-01-13
CA2272460A1 (fr) 1998-05-28
JP2001504129A (ja) 2001-03-27
CN1242772A (zh) 2000-01-26
ES2202647T3 (es) 2004-04-01
PT946546E (pt) 2003-11-28
EP0946546B1 (de) 2003-06-25
DE69723104D1 (de) 2003-07-31
JP4248605B2 (ja) 2009-04-02
CA2272460C (fr) 2009-11-17
AU5227698A (en) 1998-06-10
BR9713126A (pt) 2000-04-11
FR2755967B1 (fr) 1999-01-29

Similar Documents

Publication Publication Date Title
DE69723104D1 (de) Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel
HUP9901820A2 (hu) 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
DE69725608D1 (de) Indolin-2-one derivate, verfahren zu ihrer herstellung und dieseenthaltende arzneimittel
ES2176204T3 (es) Antidepresivos que contienen un derivado de xantina.
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DK0726893T3 (da) Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma
NO982222L (no) 3-(4-Subst.-piperidinyl-1)-1-(3,4-diklorfenyl)propylkarbamater og -ureaer og derivater som neurokinin-antagonister
DE69632193D1 (de) Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
DK0810991T3 (da) 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister
ATE86602T1 (de) Alpha,alpha disubstituierte n-cycloalkylalkylbenzylamine, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und ihre zwischenprodukte bei der herstellung.
ATE270665T1 (de) Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
ATE172454T1 (de) Pyridazinon derivate mit pharmazeutischer wirkung
ATE234818T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE189894T1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE59606725D1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE300530T1 (de) Azol- oder triazol-derivate, verfahren zu deren herstellung und ihre verwendung als antifungale arzneimittel
ATE501158T1 (de) Neue 2-halogen-derivate von 5-o- desosaminylerythronolid a, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE207056T1 (de) Diphenylalkyl-tetrahydropyridine, verfahren zu ihren herstellung und diese enthaltende arzneimittel
DE69837628D1 (de) Aminderivate, verfahren zu ihrer herstellung und ihre verwendung als antimykotische mittel
NO20022778D0 (no) Fremgangsmåte for fremstilling av 2-(2-brometyl)-naftalen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946546

Country of ref document: EP